Reg IV: A Candidate Marker of Metastatic Hormone Refractory Prostate Cancer

Abstract

In our previous in situ hybridization studies of prostate tissue arrays RegIV was shown to be strongly expressed by a majority of metastatic hormone refractory tumors (HRPC) and weaker RegIV expression was found in a subset of primary tumors but not expressed by normal tissue. Our goal is to better understand the role of RegIV in prostate cancer progression and to determine its possible use as a diagnostic marker for early and metastatic prostate cancers. We have developed and affinity purified a polyclonal anti-RegIV that has successfully been tested by immunohistochemistry on positive and negative controls. In vitro studies show cells overexpressing RegIV have a growth advantage and we have successfully made two si-RegIV constructs to knock down RegIV RNA and protein expression and in vivo studies are currently in progress.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2007
Accession Number
ADA471247

Entities

People

  • Robert E. Reiter

Organizations

  • University of California, Los Angeles

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biological Staining And Labeling
  • Biomedical Research
  • Cancer
  • Cells
  • Culture Media
  • Culture Techniques
  • Cysteine
  • Department Of Defense
  • Diseases And Disorders
  • Gene Expression
  • Immunohistochemistry
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Tissues

Fields of Study

  • Biology
  • Medicine

Readers

  • Molecular Genetics
  • Mycotoxin ecology in Amazonian ecosystems.
  • Prostate Cancer Biology.